The Role of Targeted Focal Therapy in the Management of Low-Risk Prostate Cancer: Update on Current Challenges
Prostate cancer is one of the most prevalent cancers among men in the United States, second only to nonmelanomatous skin cancer. Since prostate-specific antigen (PSA) testing came into widespread use in the late 1980s, there has been a sharp increase in annual prostate cancer incidence. Cancer-speci...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Prostate Cancer |
| Online Access: | http://dx.doi.org/10.1155/2012/587139 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832560454345424896 |
|---|---|
| author | Daniel W. Smith Diliana Stoimenova Khadijah Eid Al Barqawi |
| author_facet | Daniel W. Smith Diliana Stoimenova Khadijah Eid Al Barqawi |
| author_sort | Daniel W. Smith |
| collection | DOAJ |
| description | Prostate cancer is one of the most prevalent cancers among men in the United States, second only to nonmelanomatous skin cancer. Since prostate-specific antigen (PSA) testing came into widespread use in the late 1980s, there has been a sharp increase in annual prostate cancer incidence. Cancer-specific mortality, though, is relatively low. The majority of these cancers will not progress to mortal disease, yet most men who are diagnosed opt for treatment as opposed to observation or active surveillance (AS). These men are thus burdened with the morbidities associated with aggressive treatments, commonly incontinence and erectile dysfunction, without receiving a mortality benefit. It is therefore necessary to both continue investigating outcomes associated with AS and to develop less invasive techniques for those who desire treatment but without the significant potential for quality-of-life side effects seen with aggressive modalities. The goals of this paper are to discuss the problems of overdiagnosis and overtreatment since the advent of PSA screening as well as the potential for targeted focal therapy (TFT) to bridge the gap between AS and definitive therapies. Furthermore, patient selection criteria for TFT, costs, side effects, and brachytherapy template-guided three-dimensional mapping biopsies (3DMB) for tumor localization will also be explored. |
| format | Article |
| id | doaj-art-cdbd633fa4a34eeaade714c1a7b22cfb |
| institution | Kabale University |
| issn | 2090-3111 2090-312X |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Prostate Cancer |
| spelling | doaj-art-cdbd633fa4a34eeaade714c1a7b22cfb2025-02-03T01:27:33ZengWileyProstate Cancer2090-31112090-312X2012-01-01201210.1155/2012/587139587139The Role of Targeted Focal Therapy in the Management of Low-Risk Prostate Cancer: Update on Current ChallengesDaniel W. Smith0Diliana Stoimenova1Khadijah Eid2Al Barqawi3Division of Urology, UC Denver School of Medicine, Academic Office One Building, Room 5602, 12631 East 17th Avenue C-319, Aurora, CO 80045, USADivision of Urology, UC Denver School of Medicine, Academic Office One Building, Room 5602, 12631 East 17th Avenue C-319, Aurora, CO 80045, USADivision of Urology, UC Denver School of Medicine, Academic Office One Building, Room 5602, 12631 East 17th Avenue C-319, Aurora, CO 80045, USADivision of Urology, UC Denver School of Medicine, Academic Office One Building, Room 5602, 12631 East 17th Avenue C-319, Aurora, CO 80045, USAProstate cancer is one of the most prevalent cancers among men in the United States, second only to nonmelanomatous skin cancer. Since prostate-specific antigen (PSA) testing came into widespread use in the late 1980s, there has been a sharp increase in annual prostate cancer incidence. Cancer-specific mortality, though, is relatively low. The majority of these cancers will not progress to mortal disease, yet most men who are diagnosed opt for treatment as opposed to observation or active surveillance (AS). These men are thus burdened with the morbidities associated with aggressive treatments, commonly incontinence and erectile dysfunction, without receiving a mortality benefit. It is therefore necessary to both continue investigating outcomes associated with AS and to develop less invasive techniques for those who desire treatment but without the significant potential for quality-of-life side effects seen with aggressive modalities. The goals of this paper are to discuss the problems of overdiagnosis and overtreatment since the advent of PSA screening as well as the potential for targeted focal therapy (TFT) to bridge the gap between AS and definitive therapies. Furthermore, patient selection criteria for TFT, costs, side effects, and brachytherapy template-guided three-dimensional mapping biopsies (3DMB) for tumor localization will also be explored.http://dx.doi.org/10.1155/2012/587139 |
| spellingShingle | Daniel W. Smith Diliana Stoimenova Khadijah Eid Al Barqawi The Role of Targeted Focal Therapy in the Management of Low-Risk Prostate Cancer: Update on Current Challenges Prostate Cancer |
| title | The Role of Targeted Focal Therapy in the Management of Low-Risk Prostate Cancer: Update on Current Challenges |
| title_full | The Role of Targeted Focal Therapy in the Management of Low-Risk Prostate Cancer: Update on Current Challenges |
| title_fullStr | The Role of Targeted Focal Therapy in the Management of Low-Risk Prostate Cancer: Update on Current Challenges |
| title_full_unstemmed | The Role of Targeted Focal Therapy in the Management of Low-Risk Prostate Cancer: Update on Current Challenges |
| title_short | The Role of Targeted Focal Therapy in the Management of Low-Risk Prostate Cancer: Update on Current Challenges |
| title_sort | role of targeted focal therapy in the management of low risk prostate cancer update on current challenges |
| url | http://dx.doi.org/10.1155/2012/587139 |
| work_keys_str_mv | AT danielwsmith theroleoftargetedfocaltherapyinthemanagementoflowriskprostatecancerupdateoncurrentchallenges AT dilianastoimenova theroleoftargetedfocaltherapyinthemanagementoflowriskprostatecancerupdateoncurrentchallenges AT khadijaheid theroleoftargetedfocaltherapyinthemanagementoflowriskprostatecancerupdateoncurrentchallenges AT albarqawi theroleoftargetedfocaltherapyinthemanagementoflowriskprostatecancerupdateoncurrentchallenges AT danielwsmith roleoftargetedfocaltherapyinthemanagementoflowriskprostatecancerupdateoncurrentchallenges AT dilianastoimenova roleoftargetedfocaltherapyinthemanagementoflowriskprostatecancerupdateoncurrentchallenges AT khadijaheid roleoftargetedfocaltherapyinthemanagementoflowriskprostatecancerupdateoncurrentchallenges AT albarqawi roleoftargetedfocaltherapyinthemanagementoflowriskprostatecancerupdateoncurrentchallenges |